|
4th International AIDS Society Conference on HIV Pathogenesis and TreatmentSydney, Australia - July 22 - 25, 2007 |
DANISH POST-EXPOSURE PROPHYLAXIS (PEP) REGISTRY: 10 YEARS EXPERIENCE WITH THE USE OF PEP FOLLOWING HIV EXPOSURE
IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. MOPDC03
Lunding S.
1, Katzenstein T.L.2, Kronborg G.3, Lindberg J.4, Jensen J.5, Nielsen H.I.6, Pedersen C.7,
Kristensen L.8
1Helsingor Hospital, Department of Infectious Diseases, Helsingor, Denmark, 2Rigshospitalet, Department of Infectious Diseases, Copenhagen, Denmark, 3Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark,
4Skejby Hospital, Department of Infectious Diseases, Aarhus, Denmark, 5Kolding Hospital, Department of Infectious Diseases, Kolding, Denmark, 6Aalborg Hospital, Department of Infectious Diseases, Aalborg, Denmark, 7Odense Hospital, Department of
Infectious Diseases, Odense, Denmark, 8Viborg Hospital, Department of Internal Medicine, Viborg, Denmark
OBJECTIVES: To describe the use of PEP in Denmark since the first case in 1997.
METHODS: All clinics in Denmark prescribing PEP reported retrospective data on all PEP cases to the Danish PEP registry. Data from 1998 (sexual exposure)and 1999 (occupational and other blood exposure) up to sept. 2006 is presented. Data on the frequency of PEP for occupational exposures in 1997-1998 is derived from a seperate study*.
RESULTS: PEP was given to 357 patients following sexual exposure.The incidense from 1998-2006 was 5, 12, 38, 47, 43, 54, 58, 59 and 72** cases/year.78% were men, 58% were homosexual. Most frequent indication for PEP was receptive anal intercourse 41%, insertive anal intercourse 15%, receptive vaginal intercourse 20% and insertive vaginal intercourse 17%. In 29 cases (8%) the patient had been raped.In 146 cases (41%) the HIV-status of the source was unknown - of these 64% was initiated due to receptive anal intercourse. PEP was prescribed more than once to 22 patients, in 2006 alone 8 patients had PEP previously. The incidence of PEP following occupational exposure from 1997-2006 was 12,35,23,24,27,39,32,34,43 and 20** cases/year. Data from 1999-2006 (N=242) is presented. 80% had percutaneous exposures.29% were nurses, 22% doctors and 7% dentists. In 35% the HIV-status of the source was unknown - 64% of these were tested and 76% belonged to high-risk groups. Median time to PEP initiation was 10,4 hours (0,5-60) after sexual exposure and 2,0 hours (0,15-37) after occupational exposures. Of the total 599 cases, 59% completed PEP,9% stopped because the source tested negative and 5 % stopped due to adverse effects.
CONCLUSIONS: In Denmark PEP can only be prescribed by specialists in infectious diseases which ensures a qualified risk assesment. Although PEP following sexual exposure PEP is increasing, repeated administration of PEP is rare.
Download PDF of this abstract.
Download Power Point Presentation.
2007-07-22
MOPDC03
The Treatment-Prevention Nexus
Copyright © 2007 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.